186 related articles for article (PubMed ID: 20516453)
1. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer.
Morris PG; Lynch C; Feeney JN; Patil S; Howard J; Larson SM; Dickler M; Hudis CA; Jochelson M; McArthur HL
J Clin Oncol; 2010 Jul; 28(19):3154-9. PubMed ID: 20516453
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic performance of (18)F-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis.
Niikura N; Hashimoto J; Kazama T; Koizumi J; Ogiya R; Terao M; Oshitanai R; Morioka T; Tsuda B; Okamura T; Saito Y; Iwaisako K; Iwamoto T; Hayashi N; Imai Y; Tokuda Y
Breast Cancer; 2016 Jul; 23(4):662-7. PubMed ID: 26037335
[TBL] [Abstract][Full Text] [Related]
3. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.
Hahn S; Heusner T; Kümmel S; Köninger A; Nagarajah J; Müller S; Boy C; Forsting M; Bockisch A; Antoch G; Stahl A
Acta Radiol; 2011 Nov; 52(9):1009-14. PubMed ID: 21969709
[TBL] [Abstract][Full Text] [Related]
4. Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients.
Catalano OA; Nicolai E; Rosen BR; Luongo A; Catalano M; Iannace C; Guimaraes A; Vangel MG; Mahmood U; Soricelli A; Salvatore M
Br J Cancer; 2015 Apr; 112(9):1452-60. PubMed ID: 25871331
[TBL] [Abstract][Full Text] [Related]
5. Significance of hormone receptor status in comparison of 18F -FDG-PET/CT and 99mTc-MDP bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience.
Teke F; Teke M; Inal A; Kaplan MA; Kucukoner M; Aksu R; Urakci Z; Tasdemir B; Isikdogan A
Asian Pac J Cancer Prev; 2015; 16(1):387-91. PubMed ID: 25640386
[TBL] [Abstract][Full Text] [Related]
6. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
Du Y; Cullum I; Illidge TM; Ell PJ
J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hybrid
Janssen JC; Meißner S; Woythal N; Prasad V; Brenner W; Diederichs G; Hamm B; Makowski MR
Eur Radiol; 2018 Feb; 28(2):610-619. PubMed ID: 28779400
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
9. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
Ng SP; David S; Alamgeer M; Ganju V
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
[TBL] [Abstract][Full Text] [Related]
10. Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.
Hurley C; McCarville MB; Shulkin BL; Mao S; Wu J; Navid F; Daw NC; Pappo AS; Bishop MW
Pediatr Blood Cancer; 2016 Aug; 63(8):1381-6. PubMed ID: 27082077
[TBL] [Abstract][Full Text] [Related]
11. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.
Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Loidl W; Broinger G; Stoiber F; Foglman I; Langsteger W
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1766-74. PubMed ID: 18465129
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of bone metastases from breast cancer by bone scintigraphy and positron emission tomography/computed tomography imaging.
Pires AO; Borges US; Lopes-Costa PV; Gebrim LH; da Silva BB
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():138-41. PubMed ID: 25037283
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
14. A Prospective Study Comparing
Löfgren J; Mortensen J; Rasmussen SH; Madsen C; Loft A; Hansen AE; Oturai P; Jensen KE; Mørk ML; Reichkendler M; Højgaard L; Fischer BM
J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
[TBL] [Abstract][Full Text] [Related]
15. Comparison of (18)F-FDG-PET/CT with (99m)Tc-MDP bone scintigraphy for the detection of bone metastases in cancer patients.
Ozülker T; Küçüköz Uzun A; Ozülker F; Ozpaçac T
Nucl Med Commun; 2010 Jun; 31(6):597-603. PubMed ID: 20224457
[TBL] [Abstract][Full Text] [Related]
16. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype.
Dashevsky BZ; Goldman DA; Parsons M; Gönen M; Corben AD; Jochelson MS; Hudis CA; Morrow M; Ulaner GA
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1666-1673. PubMed ID: 25971426
[TBL] [Abstract][Full Text] [Related]
17. Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer.
Morris PG; Ulaner GA; Eaton A; Fazio M; Jhaveri K; Patil S; Evangelista L; Park JY; Serna-Tamayo C; Howard J; Larson S; Hudis CA; McArthur HL; Jochelson MS
Cancer; 2012 Nov; 118(22):5454-62. PubMed ID: 22517371
[TBL] [Abstract][Full Text] [Related]
18. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
19. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Bone Lesions with
van Es SC; Velleman T; Elias SG; Bensch F; Brouwers AH; Glaudemans AWJM; Kwee TC; Iersel MW; Maduro JH; Oosting SF; de Vries EGE; Schröder CP
J Nucl Med; 2021 Feb; 62(2):177-183. PubMed ID: 32817140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
